SNSE insider transaction filings
Sensei Biotherapeutics, Inc. — 43 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-12. Screen SNSE transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for SNSE between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Sensei Biotherapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-12 | 4 | Gerry Christopher — President & PEO | Grant/award (A): 220,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Holmen Bob — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Donenberg Phillip B. — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Peyer James — 10% owner | Sale (S): 24,524 @ $20 · Sale (S): 476 @ $21.14 | EDGAR |
| 2026-06-01 | 4 | Cambrian BioPharma Inc — 10% owner | Sale (S): 24,524 @ $20 · Sale (S): 476 @ $21.14 | EDGAR |
| 2026-05-15 | 4 | MILLENNIUM MANAGEMENT LLC — 10% owner ICS OPPORTUNITIES II LLC — 10% owner MILLENNIUM GROUP MANAGEMENT LLC — 10% owner ENGLANDER ISRAEL A — 10% owner | Purchase (P): 26 @ $33.47 · Purchase (P): 1,276 @ $34.75 · Purchase (P): 701 @ $35.55 · Sale (S): 3,099 @ $30.86 · Sale (S): 1,265 @ $31.75 · Sale (S): 1,794 @ $32.60 · +11 more | EDGAR |
| 2026-05-15 | 4 | MILLENNIUM MANAGEMENT LLC — 10% owner ICS OPPORTUNITIES II LLC — 10% owner MILLENNIUM GROUP MANAGEMENT LLC — 10% owner ENGLANDER ISRAEL A — 10% owner | Purchase (P): 616 @ $24.69 · Purchase (P): 1,770 @ $25.32 · Purchase (P): 1,048 @ $26.73 · Purchase (P): 17 @ $27.78 · Purchase (P): 186 @ $30.48 · Purchase (P): 1,957 @ $31.45 · +11 more | EDGAR |
| 2026-05-15 | 4 | MILLENNIUM MANAGEMENT LLC — 10% owner ICS OPPORTUNITIES II LLC — 10% owner MILLENNIUM GROUP MANAGEMENT LLC — 10% owner ENGLANDER ISRAEL A — 10% owner | Purchase (P): 778 @ $27.23 · Purchase (P): 1,327 @ $27.95 · Purchase (P): 2,601 @ $28.85 · Purchase (P): 1,025 @ $29.98 · Sale (S): 583 @ $26.88 · Sale (S): 1,274 @ $28.69 · +11 more | EDGAR |
| 2026-04-14 | 4 | Craver Josiah — PFO & PAO | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2026-04-14 | 4 | Donenberg Phillip B. — Director | Grant/award (A): 23,100 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Parikh Anand Kiran — Chief Operating Officer, Director | Grant/award (A): 809,822 (derivative) · Grant/award (A): 92,533 (derivative) · Grant/award (A): 56,673 (derivative) · Grant/award (A): 1,239,305 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Donenberg Phillip B. — Director | Grant/award (A): 1,900 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | Peyer James — 10% owner | Sale (S): 3,105 @ $8.59 · Sale (S): 2,666 @ $7.95 · Option exercise (M): 395 @ $6.40 · Sale (S): 395 @ $8.04 · Sale (S): 446 @ $7.92 · Option exercise (M): 395 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | Cambrian BioPharma Inc — 10% owner | Sale (S): 3,105 @ $8.59 · Sale (S): 2,666 @ $7.95 · Option exercise (M): 395 @ $6.40 · Sale (S): 395 @ $8.04 · Sale (S): 446 @ $7.92 · Option exercise (M): 395 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | Peyer James — 10% owner | Sale (S): 5,000 @ $9.06 · Sale (S): 14,508 @ $11.40 · Sale (S): 1,745 @ $12.29 · Sale (S): 42 @ $13.16 | EDGAR |
| 2025-12-08 | 4 | Cambrian BioPharma Inc — 10% owner | Sale (S): 5,000 @ $9.06 · Sale (S): 14,508 @ $11.40 · Sale (S): 1,745 @ $12.29 · Sale (S): 42 @ $13.16 | EDGAR |
| 2025-05-23 | 4 | Peyer James — Director, 10% owner | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | Humer Kristian — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | Holmen Bob — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | Cambrian BioPharma Inc — 10% owner | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | RINGO WILLIAM R — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | RICKS THOMAS G — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Celebi John — PRESIDENT AND CEO, Director | Tax withholding (F): 5,558 @ $0.48 | EDGAR |
| 2025-02-26 | 4 | van der Horst Edward — CHIEF SCIENTIFIC OFFICER | Tax withholding (F): 2,276 @ $0.48 | EDGAR |
| 2025-02-14 | 4 | Krebs Stephanie — Chief Business Officer | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | Craver Josiah — Principal Financial Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | Celebi John — PRESIDENT AND CEO, Director | Grant/award (A): 360,000 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | van der Horst Edward — CHIEF SCIENTIFIC OFFICER | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | van der Horst Edward — CHIEF SCIENTIFIC OFFICER | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | Celebi John — PRESIDENT AND CEO, Director | Grant/award (A): 355,000 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | Krebs Stephanie — Chief Business Officer | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | Craver Josiah — Principal Financial Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Peyer James — Director, 10% owner | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Holmen Bob — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | English Jessie — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Humer Kristian — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Vojta Deneen — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Cambrian BioPharma Inc — 10% owner | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | RINGO WILLIAM R — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | RICKS THOMAS G — Director | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2024-02-16 | 4 | van der Horst Edward — CHIEF SCIENTIFIC OFFICER | Tax withholding (F): 2,843 @ $0.79 · Grant/award (A): 125,000 (derivative) @ $0 · Grant/award (A): 90,102 (derivative) @ $0 | EDGAR |
| 2024-02-16 | 4 | Celebi John — PRESIDENT AND CEO, Director | Tax withholding (F): 5,891 @ $0.79 · Grant/award (A): 315,000 (derivative) @ $0 · Grant/award (A): 165,889 (derivative) @ $0 | EDGAR |
| 2024-02-16 | 4 | Colgan Erin — CHIEF FINANCIAL OFFICER | Tax withholding (F): 3,627 @ $0.79 · Grant/award (A): 125,000 (derivative) @ $0 · Grant/award (A): 94,128 (derivative) @ $0 | EDGAR |
Recent 8-K events — Sensei Biotherapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-18 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-15 | 8-K | 1.02 — Termination of a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-22 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-05-21 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SNSE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →